by Peter Ciszewski | Apr 22, 2018
Shauna Horvath, Director of Strategic Planning at Cambridge BioMarketing, discusses how Cambridge BioMarketing has evolved over the past 15 years to focus exclusively on rare diseases....
by Peter Ciszewski | Apr 21, 2018
Yuval Cohen, PhD, CEO of Corbus Pharmaceuticals provides a compnay overview focusing on Lenabasum, a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in...
by Peter Ciszewski | Apr 19, 2018
Jeff Marrazzo, Co-Founder and CEO of Spark Therapeutics, discusses working with advocacy groups and the importance of recognizing patients in all the work they...
by Peter Ciszewski | Apr 18, 2018
The Food and Drug Administration (FDA) approved Crysvita (burosumab-twza) as the first treatment for patients with x-linked hypophosphatemia (XLH). Ultragenyx Pharmaceutical and Kyowa Hakko Kirin developed Crysvita, which is an antibody that blocks fibroblast growth...
by Peter Ciszewski | Apr 18, 2018
Rob Neville of Savara Pharmaceuticals discusses his company’s cystic fibrosis program. Savara initiated its pivotal Phase 3 AVAIL Study of AeroVanc for the treatment of MRSA in Cystic Fibrosis patients in Q3 2017. There are about 30,000 people living with...
